Literature DB >> 9771942

Specificities of human glutathione S-transferase isozymes toward anti-diol epoxides of methylchrysenes.

X Hu1, A Pal, J Krzeminski, S Amin, Y C Awasthi, P Zimniak, S V Singh.   

Abstract

The specificities of human glutathione (GSH) S-transferase (GST) isozymes of class alpha (hGSTA1-1), mu (hGSTM1-1) and pi (hGSTP1-1), including the three allelic forms of hGSTP1-1 [hGSTP1-1(I104,A113), hGSTP1-1(V104,A113) and hGSTP1-1(V104,V113)], in catalyzing the GSH conjugation of anti-diol epoxide stereoisomers of 5-methylchrysene (anti-5-MeCDE) have been examined. The specific activities of human GSTs were significantly higher toward (+)-anti-5-MeCDE than toward the (-)-enantiomer of anti-5-MeCDE. All three variants of hGSTP1-1 were significantly more efficient than either hGSTA1-1 or hGSTM1-1 in GSH conjugation of (+)-anti-5-MeCDE. The catalytic efficiencies of hGSTP1-1 variants toward (+)-anti-5-MeCDE were in the order hGSTP1-1(I104,A113) > hGSTP1-1(V104,V113) > hGSTP1-1(V104,A113). The present study suggests that the I104,A113 allele, which is most frequent in human populations, may play a major role in the detoxification of (+)-anti-5-MeCDE. This may point to specificity, because previous studies from our laboratory have shown that the hGSTP1-1(V104,V113) isoform is significantly more efficient than the other two variants of hGSTP1-1 in catalyzing GSH conjugation of (+)-anti-7R,8S-dihydroxy-9S,10R-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene [(+)-anti-BPDE], the ultimate carcinogen of benzo[a]pyrene. Even though the mechanism of the differences in the activities of hGSTP1-1 variants toward anti-5-MeCDE versus anti-BPDE remains to be elucidated, it seems that the molecular configuration of the diol epoxide is an important determinant of the activity of hGSTP1-1 isoforms toward polycyclic aromatic hydrocarbon diol epoxides.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9771942     DOI: 10.1093/carcin/19.9.1685

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

2.  Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.

Authors:  Radojka M Savic; Morton J Cowan; Christopher C Dvorak; Sung-Yun Pai; Luis Pereira; Imke H Bartelink; Jaap J Boelens; Robbert G M Bredius; Rob F Wynn; Geoff D E Cuvelier; Peter J Shaw; Mary A Slatter; Janel Long-Boyle
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-09       Impact factor: 5.742

3.  Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus.

Authors:  Zdenek Kala; Jiří Dolina; Filip Marek; Lydie Izakovicova Holla
Journal:  J Hum Genet       Date:  2007-05-03       Impact factor: 3.172

4.  Cytotoxicity and mutagenicity of 5-methylchrysene and its 1,2-dihydrodiol in V79MZ cells modified to express human CYP1A1 or CYP1B1, in the presence or absence of human GSTP1 coexpression.

Authors:  Sarfaraz Ahmad; Sandra L Kabler; Lisa Rudd; Shantu Amin; Johannes Doehmer; Charles S Morrow; Alan J Townsend
Journal:  Toxicol Lett       Date:  2008-10-22       Impact factor: 4.372

5.  Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.

Authors:  Janel R Long-Boyle; Rada Savic; Shirley Yan; Imke Bartelink; Lisa Musick; Deborah French; Jason Law; Biljana Horn; Morton J Cowan; Christopher C Dvorak
Journal:  Ther Drug Monit       Date:  2015-04       Impact factor: 3.681

6.  Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.

Authors:  L'Aurelle Johnson; Paul J Orchard; K Scott Baker; Richard Brundage; Qing Cao; Xinjing Wang; Erica Langer; Sharein Farag-El Maasah; Julie A Ross; Rory Remmel; Pamala A Jacobson
Journal:  J Clin Pharmacol       Date:  2008-07-17       Impact factor: 3.126

7.  Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence.

Authors:  Paul J Dluzniewski; Ming-Hsi Wang; Siqun Lilly Zheng; Angelo M De Marzo; Charles G Drake; Helen L Fedor; Alan W Partin; Misop Han; M Daniele Fallin; Jianfeng Xu; William B Isaacs; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-02       Impact factor: 4.254

Review 8.  Activating p53 function by targeting RLIP.

Authors:  Sharad S Singhal; David Horne; Jyotsana Singhal; Sanjay Awasthi; Ravi Salgia
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2021-01-15       Impact factor: 11.414

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.